抗髓鞘相关糖蛋白神经病：最新进展。

IF 2.3 Q3 CLINICAL NEUROLOGY

Neurology. Clinical practice Pub Date : 2025-02-01 Epub Date: 2024-10-08 DOI:10.1212/CPJ.0000000000200368

Jennifer Morganroth, Chafic Karam

{"title":"抗髓鞘相关糖蛋白神经病：最新进展。","authors":"Jennifer Morganroth, Chafic Karam","doi":"10.1212/CPJ.0000000000200368","DOIUrl":null,"url":null,"abstract":"Background: The purpose of this review is to give an update on myelin-associated glycoprotein (MAG) neuropathy.Recent findings: There are several recent developments in anti-MAG neuropathy, with the major one being the retrospective analysis of 50 clinical trials that showed that at least a 50% reduction in anti-MAG levels is associated with a therapeutic response. Other updates address antibody levels needed for a positive test, response, and exacerbations to therapy and the type of antibody more associated with malignancy.Implications for practice: Anti-MAG neuropathy is heterogeneous, and the natural history of the disease continues to be refined. Treatment options are being explored for refractory disease.","PeriodicalId":19136,"journal":{"name":"Neurology. Clinical practice","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464236/pdf/","citationCount":"0","resultStr":"{\"title\":\"Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments.\",\"authors\":\"Jennifer Morganroth, Chafic Karam\",\"doi\":\"10.1212/CPJ.0000000000200368\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The purpose of this review is to give an update on myelin-associated glycoprotein (MAG) neuropathy.Recent findings: There are several recent developments in anti-MAG neuropathy, with the major one being the retrospective analysis of 50 clinical trials that showed that at least a 50% reduction in anti-MAG levels is associated with a therapeutic response. Other updates address antibody levels needed for a positive test, response, and exacerbations to therapy and the type of antibody more associated with malignancy.Implications for practice: Anti-MAG neuropathy is heterogeneous, and the natural history of the disease continues to be refined. Treatment options are being explored for refractory disease.\",\"PeriodicalId\":19136,\"journal\":{\"name\":\"Neurology. Clinical practice\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464236/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology. Clinical practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1212/CPJ.0000000000200368\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology. Clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1212/CPJ.0000000000200368","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：本综述旨在介绍髓鞘相关糖蛋白（MAG）神经病变的最新进展：抗 MAG 神经病变方面有几项最新进展，其中最主要的是对 50 项临床试验的回顾性分析，分析表明抗 MAG 水平至少降低 50%与治疗反应相关。其他更新还涉及阳性检测所需的抗体水平、对治疗的反应和加重，以及与恶性肿瘤更相关的抗体类型：抗 MAG 神经病变具有异质性，该病的自然史仍在不断完善。目前正在探索针对难治性疾病的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments.

Background: The purpose of this review is to give an update on myelin-associated glycoprotein (MAG) neuropathy.

Recent findings: There are several recent developments in anti-MAG neuropathy, with the major one being the retrospective analysis of 50 clinical trials that showed that at least a 50% reduction in anti-MAG levels is associated with a therapeutic response. Other updates address antibody levels needed for a positive test, response, and exacerbations to therapy and the type of antibody more associated with malignancy.

Implications for practice: Anti-MAG neuropathy is heterogeneous, and the natural history of the disease continues to be refined. Treatment options are being explored for refractory disease.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Neurology. Clinical practice CLINICAL NEUROLOGY-

CiteScore

4.00

自引率

0.00%

发文量

期刊介绍： Neurology® Genetics is an online open access journal publishing peer-reviewed reports in the field of neurogenetics. The journal publishes original articles in all areas of neurogenetics including rare and common genetic variations, genotype-phenotype correlations, outlier phenotypes as a result of mutations in known disease genes, and genetic variations with a putative link to diseases. Articles include studies reporting on genetic disease risk, pharmacogenomics, and results of gene-based clinical trials (viral, ASO, etc.). Genetically engineered model systems are not a primary focus of Neurology® Genetics, but studies using model systems for treatment trials, including well-powered studies reporting negative results, are welcome.